X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (106915) 106915
Magazine Article (73) 73
Newsletter (60) 60
Newspaper Article (35) 35
Transcript (30) 30
Publication (26) 26
Book / eBook (13) 13
Book Review (10) 10
Book Chapter (8) 8
Conference Proceeding (5) 5
Dissertation (5) 5
Reference (3) 3
Report (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102889) 102889
antineoplastic combined chemotherapy protocols - therapeutic use (71609) 71609
female (69191) 69191
male (56950) 56950
middle aged (55113) 55113
oncology (53859) 53859
aged (46139) 46139
adult (44479) 44479
chemotherapy (33322) 33322
treatment outcome (27063) 27063
cancer (25914) 25914
antineoplastic combined chemotherapy protocols - adverse effects (25177) 25177
antineoplastic combined chemotherapy protocols - administration & dosage (21944) 21944
cisplatin - administration & dosage (20235) 20235
combined modality therapy (17668) 17668
fluorouracil - administration & dosage (15879) 15879
doxorubicin - administration & dosage (14659) 14659
cyclophosphamide - administration & dosage (14325) 14325
prognosis (13969) 13969
neoplasm staging (13815) 13815
drug administration schedule (13033) 13033
aged, 80 and over (12924) 12924
disease-free survival (12367) 12367
survival rate (12228) 12228
hematology (12175) 12175
therapy (11758) 11758
animals (11446) 11446
care and treatment (11404) 11404
breast neoplasms - drug therapy (10825) 10825
adolescent (10605) 10605
retrospective studies (10513) 10513
vincristine - administration & dosage (10206) 10206
cisplatin (10156) 10156
survival analysis (10070) 10070
lung neoplasms - drug therapy (10041) 10041
survival (9513) 9513
follow-up studies (9291) 9291
medicine & public health (9197) 9197
antineoplastic agents - therapeutic use (8966) 8966
chemotherapy, adjuvant (8258) 8258
antineoplastic agents - administration & dosage (8184) 8184
etoposide - administration & dosage (8150) 8150
remission induction (8055) 8055
paclitaxel - administration & dosage (7684) 7684
research (7504) 7504
pharmacology & pharmacy (7501) 7501
deoxycytidine - analogs & derivatives (7436) 7436
trial (7362) 7362
carcinoma (7252) 7252
mice (7235) 7235
dose-response relationship, drug (7194) 7194
surgery (6927) 6927
radiotherapy (6794) 6794
carboplatin - administration & dosage (6652) 6652
deoxycytidine - administration & dosage (6618) 6618
tumors (6608) 6608
breast cancer (6483) 6483
methotrexate - administration & dosage (6461) 6461
child (6459) 6459
analysis (6436) 6436
cell line, tumor (6350) 6350
prospective studies (6166) 6166
hematology, oncology and palliative medicine (6070) 6070
time factors (5999) 5999
antineoplastic agents (5980) 5980
carcinoma, non-small-cell lung - drug therapy (5976) 5976
breast neoplasms - pathology (5965) 5965
adenocarcinoma - drug therapy (5900) 5900
prednisone - administration & dosage (5854) 5854
metastasis (5800) 5800
paclitaxel (5632) 5632
neoplasm metastasis (5580) 5580
combination (5533) 5533
drug therapy (5533) 5533
antimitotic agents (5439) 5439
health aspects (5410) 5410
antineoplastic combined chemotherapy protocols - pharmacology (5176) 5176
leucovorin - administration & dosage (5166) 5166
young adult (5027) 5027
fluorouracil (4992) 4992
clinical trials (4908) 4908
apoptosis (4895) 4895
neoplasms - drug therapy (4800) 4800
cyclophosphamide (4785) 4785
cytarabine - administration & dosage (4747) 4747
clinical trials as topic (4733) 4733
colorectal neoplasms - drug therapy (4724) 4724
doxorubicin (4668) 4668
child, preschool (4636) 4636
risk factors (4566) 4566
taxoids - administration & dosage (4530) 4530
phase-ii (4522) 4522
antineoplastic agents - adverse effects (4515) 4515
ovarian neoplasms - drug therapy (4495) 4495
organoplatinum compounds - administration & dosage (4441) 4441
toxicity (4420) 4420
lung neoplasms - pathology (4405) 4405
docetaxel (4347) 4347
expression (4296) 4296
vinblastine - administration & dosage (4283) 4283
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Online Resources - Online (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (97001) 97001
Japanese (7435) 7435
German (1251) 1251
Chinese (1237) 1237
French (1205) 1205
Russian (743) 743
Spanish (497) 497
Polish (310) 310
Italian (296) 296
Hungarian (146) 146
Czech (73) 73
Dutch (57) 57
Hebrew (32) 32
Bulgarian (27) 27
Ukrainian (27) 27
Danish (26) 26
Portuguese (24) 24
Serbian (19) 19
Romanian (17) 17
Norwegian (15) 15
Croatian (13) 13
Korean (13) 13
Finnish (11) 11
Swedish (9) 9
Slovak (6) 6
Lithuanian (5) 5
Turkish (3) 3
Afrikaans (1) 1
Arabic (1) 1
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
... than standard chemotherapy in patients with ALK -positive lung cancer. Rearrangements of the anaplastic lymphoma kinase ( ALK... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
... to HER‐2 positive disease treated with trastuzumab, in combination with chemotherapy, in first... 
Camptothecin | Stomach | Anthracyclines | Gastroenterology & hepatology | Cancer: other gastrointestinal | Palliation | Docetaxel | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Randomized Controlled Trials as Topic | Irinotecan | Chemotherapy | Treatment | Taxoids | Stomach Neoplasms | Medicine General & Introductory Medical Sciences | Fluorouracil | Cancer | 1ST-LINE TREATMENT | OLDER-ADULT PATIENTS | COLONY-STIMULATING FACTOR | Humans | Anthracyclines [administration & dosage] | Cisplatin [administration & dosage] | HIGH-DOSE 5-FLUOROURACIL | Fluorouracil [administration & dosage] | MEDICINE, GENERAL & INTERNAL | analogs & derivatives | RANDOMIZED PHASE-II | ADVANCED GASTROINTESTINAL CANCER | mortality | Taxoids [administration & dosage] | Antineoplastic Combined Chemotherapy Protocols [therapeutic use] | QUALITY-OF-LIFE | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Camptothecin [administration & dosage | Stomach Neoplasms [drug therapy | S-1 PLUS CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Stomach Neoplasms - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
...) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
.... The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
.... We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article